Marker Therapeutics (MRKR) Interest Expenses (2010 - 2026)

Marker Therapeutics (MRKR) has reported Interest Expenses for 16 consecutive years, with $354429.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses changed N/A year-over-year to $354429.0; the TTM figure through Mar 2026 stood at $354429.0 (down 83.58% YoY), while the FY2025 annual figure was $43.3 million, up 5.68% from the prior year.
• Interest Expenses fell to $354429.0 in Q1 2026 per MRKR's latest filing, from $563368.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $14.6 million in Q2 2022 and bottomed at $11000.0 in Q2 2025.
• Historically, Interest Expenses has averaged $2.7 million across 5 years, with a median of $563368.0 in 2025.
• Annual changes were most pronounced in 2023 — Interest Expenses jumped 2819.3% — and 2025, when it plunged 99.08%.
• Marker Therapeutics' Interest Expenses stood at $206000.0 in 2022, then soared by 539.43% to $1.3 million in 2023, then slumped by 71.32% to $377767.0 in 2024, then jumped by 49.13% to $563368.0 in 2025, then slumped by 37.09% to $354429.0 in 2026.
• Business Quant data shows MRKR's Interest Expenses at $354429.0 in Q1 2026, $563368.0 in Q4 2025, and $11000.0 in Q2 2025.